These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17563735)

  • 1. Competing risk analysis using R: an easy guide for clinicians.
    Scrucca L; Santucci A; Aversa F
    Bone Marrow Transplant; 2007 Aug; 40(4):381-7. PubMed ID: 17563735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression modeling of competing risk using R: an in depth guide for clinicians.
    Scrucca L; Santucci A; Aversa F
    Bone Marrow Transplant; 2010 Sep; 45(9):1388-95. PubMed ID: 20062101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant depression as risk factor for survival of patients undergoing allogeneic haematopoietic stem cell transplantation.
    Grulke N; Larbig W; Kächele H; Bailer H
    Psychooncology; 2008 May; 17(5):480-7. PubMed ID: 17879971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Major statistical software usable in epidemiology].
    Binquet C; Verret C; Chêne G; Salmi LR; Letenneur L; Palmer G; Hajjar M; Salamon R
    Rev Epidemiol Sante Publique; 1998 Sep; 46(4):329-36. PubMed ID: 9805737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicians' prognostic estimates of survival for patients undergoing allogeneic hematopoietic stem cell transplantation.
    Grulke N; Bunjes D; Larbig W; Kächele H; Bailer H
    J Psychosom Res; 2008 Jul; 65(1):61-6. PubMed ID: 18582613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.
    Schetelig J; Bornhäuser M; Schmid C; Hertenstein B; Schwerdtfeger R; Martin H; Stelljes M; Hegenbart U; Schäfer-Eckart K; Füssel M; Wiedemann B; Thiede C; Kienast J; Baurmann H; Ganser A; Kolb HJ; Ehninger G
    J Clin Oncol; 2008 Nov; 26(32):5183-91. PubMed ID: 18768435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence.
    Rao K; Darrington DL; Schumacher JJ; Devetten M; Vose JM; Loberiza FR
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1508-14. PubMed ID: 18022581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
    Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.
    Mikulska M; Raiola AM; Bruno B; Furfaro E; Van Lint MT; Bregante S; Ibatici A; Del Bono V; Bacigalupo A; Viscoli C
    Bone Marrow Transplant; 2009 Sep; 44(6):361-70. PubMed ID: 19308042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual physician practice variation in hematopoietic cell transplantation.
    Lee SJ; Joffe S; Artz AS; Champlin RE; Davies SM; Jagasia M; Kernan NA; Loberiza FR; Soiffer RJ; Eapen M
    J Clin Oncol; 2008 May; 26(13):2162-70. PubMed ID: 18378566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
    Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
    Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remote access methods for exploratory data analysis and statistical modelling: Privacy-Preserving Analytics.
    Sparks R; Carter C; Donnelly JB; O'Keefe CM; Duncan J; Keighley T; McAullay D
    Comput Methods Programs Biomed; 2008 Sep; 91(3):208-22. PubMed ID: 18495290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
    Willemze AJ; Geskus RB; Noordijk EM; Kal HB; Egeler RM; Vossen JM
    Bone Marrow Transplant; 2007 Aug; 40(4):319-27. PubMed ID: 17572715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The haploidentical option for high-risk haematological malignancies.
    Aversa F; Reisner Y; Martelli MF
    Blood Cells Mol Dis; 2008; 40(1):8-12. PubMed ID: 17905610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.